PCP
CPRX

Perbak Capital Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Perbak Capital Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Buy
+10,337
New +$246K 0.06% 271

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Perbak Capital Partners's CPRX Position: Q1 2026 in Review

Perbak Capital Partners opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 10,337 shares worth $256K. The stake represents 0.06% of the portfolio and ranks #271 among its holdings.

380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Perbak Capital Partners held 10,337 shares of Catalyst Pharmaceutical worth $256K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Perbak Capital Partners position in Q1 2026.
  • Catalyst Pharmaceutical made up 0.06% of Perbak Capital Partners's portfolio in Q1 2026, its #271 holding.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.